Tratamento de Carcinomatose Meníngea por Quimioterapia Intratecal Através de Catéter Reservatório de Ommaya: Experiência de um Centro Neurocirúrgico

Abstract

RESUMOIntrodução: A carcinomatose meníngea consiste na infiltração de células tumorais ao longo das leptomeninges e espaço subaracnoideu, encontrando-se associada a uma sobrevida média de 2 -5 meses. As indicações sobre a modalidade mais adequada de tratamento permanecem tema de discussão, sendo fundamental um correto conhecimento da história natural da doença e da dualidade risco-benefício para uma decisão terapêutica interdisciplinar. Results: Twenty three patients were included (19 females, four males) with median age of 56.1 ± 2.2 years. The primary tumour was: breast -16 patients, lung -four patients, stomach, bladder and cervix -one patient each. No complications were seen (infection, intracranial haematoma or CSF fistula). The median survival was 26.4 ± 7.7 weeks, range between nine days and 118 weeks (21/23 patients). Male gender was related to poor prognosis in crude analysis (p value = 0.0032). Breast adenocarcinoma was related with better prognosis in adjust analysis (p value = 0.036, HR: 4.36 ± 3.06; 95% IC: 1.10 -17.25). Longer time between initial tumour and meningeal carcinomatosis diagnosis was related to a better outcome but without statistical significance. Discussion: Despite the low complication rate of Ommaya reservoir placement, the poor response to chemotherapy and the disease prognosis should be considered in patients with poor functional status. The relationship observed between the primary tumour and the overall survival supports that meningeal carcinomatosis should not be considered a disease by itself but always in the context of a systemic disease. The low incidence of breast cancer in male population might be related with it poorer prognosis. Conclusion: Meningeal carcinomatosis has a poor prognosis. Breast adenocarcinoma, longer time between initial tumour and meningeal carcinomatosis diagnosis, and age < 60 years were related with longer survival.